|Bid||2.20 x 1000|
|Ask||2.40 x 1100|
|Day's Range||2.31 - 2.40|
|52 Week Range||1.94 - 15.90|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.86|
Summit Therapeutics Reports Financial Results for the Second Quarter and Half Year Ended 31 July 2018 and Operational Progress. Oxford, UK, and Cambridge, MA, US, 20 September 2018- Summit Therapeutics ...
Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2018 on 20 September 2018. Oxford, UK, and Cambridge, MA, US, 14 September 2018- Summit Therapeutics plc, ...
Summit Therapeutics to Participate in Upcoming Investor Conferences. Oxford, UK, and Cambridge, MA, US, 14 September 2018– Summit Therapeutics plc announces that management will participate in one on one ...
Summit Therapeutics plc Summit Discovers Multiple New Mechanism Antibiotics Against Novel ESKAPE Pathogen Targets. Discovery Enabled by Discuva Platform and Proprietary Bacterial Libraries Oxford, UK, ...
Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, today announces that it has nominated SMT-571 as its lead clinical candidate from its first gonorrhoea series. New mechanism antibiotics are important in the fight against gonorrhoea, as the pathogen is becoming increasingly resistant to the only recommended treatment option. Just last week, the US Centers for Disease Control and Prevention (‘CDC’) reported preliminary data that gonorrhoea cases in the US increased by 67% between 2013 and 2017 and with resistant cases on the rise, the CDC stated that additional treatment options for gonorrhoea are urgently needed.
Oxford, UK, and Cambridge, MA, US 3 September 2018– Summit Therapeutics plc, announces that in accordance with the FCA's Disclosure and Transparency Rule 5.6. 1, the Company's issued share capital as at ...
OXFORD, United Kingdom and CAMBRIDGE, Mass., Aug. 29, 2018-- Summit Therapeutics plc announces that Mr Glyn Edwards, Chief Executive Officer, will present on the Company’ s plans to advance its new mechanism ...
NEW YORK, Aug. 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ballard ...
Summit Therapeutics plc (NASDAQ:SMMT, AIM:SUMM), a leader in antibiotic innovation, today announces that it has been awarded an additional $12 million under its contract with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response. The funds will support the Phase 3 development programme for ridinilazole, the Company’s precision new mechanism antibiotic for the treatment of C. difficile infection (‘CDI’). “BARDA’s continued support underlines the promise ridinilazole has as a potential front-line CDI treatment option which can treat the initial infection and address the key clinical issue of recurrent disease,” commented Mr Glyn Edwards, Chief Executive Officer of Summit.
OXFORD, United Kingdom and CAMBRIDGE, Mass., Aug. 06, 2018-- Summit Therapeutics plc announces that Glyn Edwards, Chief Executive Officer, will present at the Canaccord Genuity Growth Conference on 9 August ...
Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces today the publication in the journal PLOS ONE of microbiome analyses highlighting ridinilazole as a precision antibiotic in development for the treatment of C. difficile infection (‘CDI’). The clinical management of CDI is stymied by poor sustained cures due to high recurrence rates after initial infection. In a double-blind Phase 2 clinical trial, ridinilazole was highly preserving of patients’ microbiomes compared to patients treated with the broad-spectrum standard of care antibiotic vancomycin.
WASHINGTON , July 30, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Summit Therapeutics plc (NASDAQ: SMMT; AIM: SUMM) (Summit) to its coalition of companies ...
CARB-X's $4.5 million award comes just a few weeks after the company shut down on a Duchenne muscular dystrophy trial and laid off most of their employees in Cambridge.
Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces it has been awarded up to $4.5 million from CARB-X, a public-private partnership devoted to accelerating early antibiotic research and development. This award will be used to support Summit’s wholly-owned, lead series of new mechanism antibiotic compounds for gonorrhoea. Gonorrhoea is recognised as an urgent bacterial threat by the US Centers for Disease Control (‘CDC’) due to the diminishing treatment arsenal.
NEW YORK, NY / ACCESSWIRE / June 28, 2018 / Aquinox Pharmaceuticals and Summit Therapeutics both saw their shares dramatically drop on Wednesday after each company announced failed trial results. Aquinox Pharmaceuticals, Inc. shares closed down almost 85% on Wednesday and hit a new low of $2.25 on about 14.2 million shares traded. The company revealed that late-stage trial results for its bladder pain drug failed to perform better than the placebo in patients.
Summit Therapeutics plc (SUMM.L) (SMMT) today announces PhaseOut DMD has not met its primary or secondary endpoints after 48 weeks of treatment of ezutromid in patients with Duchenne muscular dystrophy (‘DMD’). PhaseOut DMD was a multi-centre, open-label Phase 2 clinical trial of the utrophin modulator, ezutromid. Based on this outcome, the Company is discontinuing its development of ezutromid and as a result, will be implementing cost reduction measures.